Contents

Current Drug Targets, Volume 14 - Number 12

Editorial

Editorial (Thematic Issue: New Mechanisms and Targets for IBD Therapy: Translational Gastroenterology Comes of Age)

, 14(12): 1377 - 1378

Silvio Danese and Laurent Peyrin-Biroulet


DOI: 10.2174/13894501113146660220




Anti-IL-12/23 in Crohn's Disease: Bench and Bedside

, 14(12): 1379 - 1384

Lukas Niederreiter, Timon Erik Adolph and Arthur Kaser


DOI: 10.2174/13894501113146660229




Janus Kinase Inhibition with Tofacitinib: Changing the Face of Inflammatory Bowel Disease Treatment

, 14(12): 1385 - 1391

Lucine Vuitton, Stéphane Koch and Laurent Peyrin-Biroulet


DOI: 10.2174/13894501113149990160




Clinical Strategies for the Blockade of IL-18 in Inflammatory Bowel Diseases

, 14(12): 1392 - 1399

Takanori Kanai, Nobuhiko Kamada and Tadakazu Hisamatsu


DOI: 10.2174/13894501113149990006




TGF-Beta Signaling Manipulation as Potential Therapy for IBD

, 14(12): 1400 - 1404

Irene Marafini, Francesca Zorzi, Sefora Codazza, Francesco Pallone and Giovanni Monteleone


DOI: 10.2174/13894501113149990157




Review: New Anti-Cytokines for IBD: What is in the Pipeline?

, 14(12): 1405 - 1420

Michael Scharl, Stephan R. Vavricka and Gerhard Rogler


DOI: 10.2174/13894501113149990159




Anti-TNF Antibodies in Inflammatory Bowel Disease: Do We Finally Know How it Works?

, 14(12): 1421 - 1432

Angelos Oikonomopoulos, Welmoed K. van Deen and Daniel W. Hommes


DOI: 10.2174/13894501113149990164




Vedolizumab for the Treatment of IBD: A Selective Therapeutic Approach Targeting Pathogenic a4b7 Cells

, 14(12): 1433 - 1443

Manol Jovani and Silvio Danese


DOI: 10.2174/13894501113146660206




Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside

, 14(12): 1444 - 1452

Manol Jovani, Gionata Fiorino and Silvio Danese


DOI: 10.2174/13894501113149990170




Cell Therapies for IBD: What Works?

, 14(12): 1453 - 1459

Elena Ricart, Aranzazu Jauregui-Amezaga, Ingrid Ordás, Susana Pinó and Anna M. Ramírez


DOI: 10.2174/13894501113146660234




Sealing the Broken Barrier in IBD: Intestinal Permeability, Epithelial Cells and Junctions

, 14(12): 1460 - 1470

Walter Fries, Alessandra Belvedere and Stefania Vetrano


DOI: 10.2174/1389450111314120011




Is There Still a Room for Azathioprine Monotherapy in Inflammatory Bowel Disease?

, 14(12): 1471 - 1479

Anne Bourrier, Philippe Seksik and Jacques Cosnes


DOI: 10.2174/13894501113149990172




Methotrexate: Should We Start Using it in Clinical Practice?

, 14(12): 1480 - 1489

Pal Miheller, Lajos S. Kiss, Michael Mandel and Peter L. Lakatos


DOI: 10.2174/13894501113149990604




Leukocyte Traffic Blockade as a Therapeutic Strategy in Inflammatory Bowel Disease

, 14(12): 1490 - 1500

Giorgos Bamias, David J. Clark and Jesús Rivera-Nieves


DOI: 10.2174/13894501113149990158




PPAR-Gamma in Ulcerative Colitis: A Novel Target for Intervention

, 14(12): 1501 - 1507

Benjamin Bertin, Laurent Dubuquoy, Jean-Frédéric Colombel and Pierre Desreumaux


DOI: 10.2174/13894501113149990162




Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target

, 14(12): 1508 - 1521

Mariangela Allocca, Manol Jovani, Gionata Fiorino, Stefan Schreiber and Silvio Danese


DOI: 10.2174/13894501113146660224




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science